CLDI Presents CLD-501 Data
Calidi Biotherapeutics presents new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2
CLDI - Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic SummitFindings highlight RedTail's potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression